D. E. Shaw & Co., Inc. Pds Biotechnology Corp Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $196,295 - $326,993	49,695 New	49,695 $246,000
Q1 2023 May 15, 2023	SELL	$5.68 - $11.99 $1 Million - $2.12 Million	-176,909 Reduced 52.08%	162,769 $1 Million
Q4 2022 Feb 14, 2023	BUY	$3.28 - $13.2 $1.07 Million - $4.29 Million	324,774 Added 2179.11%	339,678 $4.48 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $44,264 - $86,294	14,904 New	14,904 $44,000
Q2 2022 Aug 15, 2022	SELL	$3.05 - $6.68 $253,491 - $555,188	-83,112 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.78 - $8.43 $255,763 - $451,064	53,507 Added 180.74%	83,112 $514,000
Q4 2021 Feb 14, 2022	BUY	$7.76 - $14.35 $229,734 - $424,831	29,605 New	29,605 $240,000
Q2 2020 Aug 14, 2020	SELL	$0.65 - $2.6 $8,632 - $34,530	-13,281 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.08 - $4.07 $825 - $1,615	-397 Reduced 2.9%	13,281 $35,000
Q2 2019 Aug 14, 2019	SELL	$5.44 - $8.68 $137,392 - $219,222	-25,256 Reduced 64.87%	13,678 $82,000
Q1 2019 May 15, 2019	BUY	$6.8 - $10.08 $264,751 - $392,454	38,934 New	38,934 $288,000

4.22M

170K

6.7K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $38.1M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.